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Introduction
Anaphylactic reactions during cesarean sections rarely 
occur but can be fatal for both the mother and fetus. The 
incidence of anaphylaxis during general anesthesia has 
been estimated to be one case in 10,000–20,000 in the 
general population [1, 2]. It has also been reported that 
anaphylaxis during pregnancy occurs in approximately 3 
cases per 100,000 deliveries [3]. A neuromuscular blocking 
agent, rocuronium, is thought to be a common agent caus-
ing perioperative anaphylaxis [4–6]. However, no case of 
anaphylaxis caused by the rocuronium–sugammadex com-
plex has been reported. We report a suspected case of rocu-
ronium–sugammadex complex-induced anaphylactic shock 
after cesarean section. Written consent was obtained from 
the patient to publish this case report.
Case report
A 36-year-old primigravida (body weight, 65 kg; height, 
167 cm) with no history of drug allergy or surgery under-
went an elective cesarean section because of placenta 
previa. General anesthesia was scheduled to secure the 
patient’s condition in case of massive bleeding. General 
anesthesia was induced with 350 mg thiopental and 70 mg 
rocuronium. After uneventful tracheal intubation, anesthe-
sia was maintained with 1% sevoflurane and 50% nitrous 
oxide until delivery (Fig. 1). A neonate weighing 2774 g 
was delivered with Apgar scores of 8 and 9 at 1 and 5 min, 
respectively. After delivery, anesthesia was changed to total 
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intravenous anesthesia with propofol, remifentanil, and 
supplemental bolus fentanyl. Immediately after ligation 
of the placenta, 1 g flomoxef sodium was intravenously 
infused to prevent surgical site infection and 5 U oxytocin 
was slowly infused intravenously 5 min after delivery. A 
final bolus of 200 μg fentanyl was infused approximately 
15 min prior to the end of the operation. No additional 
rocuronium injection was required throughout the opera-
tion. The uneventful operation was completed in 66 min. 
The patient woke up approximately 10 min after the com-
pletion of the operation, and extubation was performed 
immediately following infusion of 200 mg sugammadex. 
Immediately after extubation, systolic arterial blood pres-
sure suddenly fell to less than 40 mmHg, and the low level 
persisted despite fluid infusion and ephedrine administra-
tion. The patient complained of dyspnea and subsequently 
became unconscious. Manual mask ventilation and reintu-
bation were successfully performed without rocuronium. 
Subsequently, her entire body became flushed, and tran-
sthoracic echocardiography revealed left ventricular col-
lapse with no right ventricle dilatation, pericardial effusion, 
or aortic dissection. Arterial blood gas analysis revealed 
hemoconcentration compared with that at the beginning 
of the operation. Hemoglobin concentration was elevated 
from 10.9 to 16.1 g/dl, and hematocrit was elevated from 
33.7 to 49.3%. We suspected a severe allergic reaction and 
continued shock treatment. Large amounts of intravascu-
lar fluids, repeat intravenous bolus of 0.1 mg epinephrine, 
and intravenous doses of 100 mg hydrocortisone, 20 mg 
famotidine, and 5 mg chlorpheniramine maleate were 
administered. After approximately 20 min, systolic arterial 
blood pressure had improved to over 100 mmHg and heart 
rate was normalized. No further anaphylactic reactions or 
other complications occurred. Mother and child were dis-
charged on the seventh postoperative day. The results of 
blood tests revealed that the serum tryptase level at the time 
of the event was significantly elevated to 21.5 μg/l (nor-
mal range 2.1–9.0 μg/l) followed by a rapid decrease to 
1.7 μg/l in a period of 24 h, strongly suggesting an ana-
phylactic reaction [7]. There was no significant increase 
in the serum histamine level (0.32 ng/ml, normal range 
0.15–1.23 ng/ml).
We initially suspected the causative agent to be sugam-
madex because cardiac collapse occurred immediately after 
its administration. The patient was readmitted to our hos-
pital 4 weeks after the event to undergo skin tests to detect 
the causative agent. The skin tests were performed by a 
dermatologist in the intensive care unit. First, a skin prick 
test of sugammadex was performed, resulting in no change. 
Then, intradermal skin tests with different concentrations 
were performed with 0.04 ml of each sample and produced 
3–4 mm wheals. The diameter of wheal and flare was not 
increased by tests with sugammadex diluted 1:1,000, 1:100, 
or undiluted. Next, we performed an intradermal skin test 
using undiluted rocuronium (10 mg/ml) in consideration 
of the historical high incidence of rocuronium-induced 
anaphylaxis. This test was performed 40 min after the 
sugammadex tests. Surprisingly, 2 min after rocuronium 
Fig. 1  Anesthesia record. × Anesthesia start and end, T intubation and extubation, concentric circles operation start and end
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administration, her vital signs rapidly progressed to a 
shock state. Systolic arterial blood pressure fell from 140 
to 70 mmHg and heart rate increased from 70 beats/min to 
140 beats/min. Her entire body showed generalized redness 
and she became dyspneic. Suspecting a possible allergic 
reaction, we started rapid management with intravenous 
fluid infusion, oxygen, and epinephrine. Her cardiorespira-
tory condition fully recovered in 20 min and there was no 
recurrence of the anaphylactic reaction.
The results of the intradermal skin tests were inconsist-
ent with our expectations that sugammadex would reveal 
positive. We speculated that the rocuronium–sugammadex 
complex was the possible causative agent of the anaphy-
lactic reaction. Hence, additional skin tests were performed 
by allergy specialists at the university hospital. First, a 
skin prick test with histamine as a positive control was 
performed and revealed a positive reaction with enlarged 
wheal reaction (from 9 × 5 to 30 × 30 mm) and itching 
paresthesia. Then, skin prick tests with rocuronium–sugam-
madex complex of different concentrations were conducted 
by pre-mixing sugammadex and rocuronium in test tubes 
(1:1 volume ratio). The diameter of wheal and a flare was 
not changed by each test with the complex diluted 1:1,000 
and 1:100. However, a markedly positive persistent flare 
and enlarged wheal response with itching paresthesia was 
recorded at the test site with 1:10 diluted complex (from 
8 × 6 to 35 × 24 mm), which was comparable to the hista-
mine positive control. No subsequent intradermal test with 
the complex was conducted because even a skin prick test 
was positive. Two weeks later, a skin prick test with undi-
luted rocuronium was performed, resulting in no change. 
An additional intradermal test with undiluted rocuronium 
revealed enlarged wheal, but it was not accompanied by 
itching paresthesia and change of vital signs. Based on the 
results of the skin tests, we ultimately concluded that the 
rocuronium–sugammadex complex was the causative agent 
of the anaphylactic reaction.
Discussion
In our patient, an anaphylactic shock occurred following a 
single intravenous dose of 200 mg sugammadex immedi-
ately after cesarean section. Considering the timing of the 
reaction, sugammadex was first suspected to be the causa-
tive agent. There are some case reports on sugammadex-
induced anaphylaxis [8, 9]. Sugammadex directly encapsu-
lates rocuronium to make it ineffective. It has recently been 
shown that sugammadex can be used for treatment of rocu-
ronium-induced anaphylaxis by direct encapsulation [10, 
11]. In contrast, to our knowledge, there has been no clini-
cal report showing anaphylaxis caused by the rocuronium–
sugammadex complex, although it has been suggested that 
this complex may provoke an allergic response [12]. It is 
surprising that the rocuronium–sugammadex complex can 
express new antigenicity even if rocuronium and sugamma-
dex separately have no antigenicity. It is still controversial 
how the rocuronium–sugammadex complex formation can 
give rise to immunological change and allergenic behavior.
We consider that the reaction of the intradermal test 
with undiluted rocuronium at the university hospital, which 
revealed enlarged wheal without itching paresthesia, was 
false-positive. It was reported that rocuronium needs to be 
diluted at least 100-fold before skin tests to confirm hyper-
sensitivity and to prevent false-positive responses [12, 13]. 
We believe our first test with undiluted rocuronium caused 
the patient to fall into a state of shock induced by formation 
of a rocuronium–sugammadex complex.
The combination of clinical, biochemical, and direct 
skin tests will enable the culprit agent to be identified. 
Some in vitro tools such as a histamine release test, flow-
cytometric analysis of activated basophils, and a specific 
IgE assay have been proposed for clinical practice, but they 
are not universally available and are not as well established 
as skin tests [14, 15]. These in vitro tests may reinforce the 
hypothesis that the rocuronium–sugammadex complex pro-
vides allergic potency in this case.
It is important for anesthesiologists to identify the causa-
tive drug of perioperative anaphylaxis to prevent recur-
rence. Physicians often believe that the agent administered 
just prior to the event is the culprit allergen, without any 
subsequent examination. However, we should keep in mind 
that the suspected agent might be different from the true 
causative drug [16]. An incorrect speculation may place 
the patient at risk of exposure to the true allergen or cause 
unnecessary avoidance of a harmless effective drug. If we 
had not pursued the cause of the allergic reaction, this case 
would have been mistaken as a patient allergic to sugam-
madex. There may be patients allergic to the rocuronium–
sugammadex complex who are considered to be allergic to 
sugammadex.
Should this patient undergo another general anesthesia, 
sugammadex must not be administered to reverse rocuro-
nium. It might be advisable to avoid rocuronium and sug-
ammadex altogether.
In conclusion, we experienced a case of anaphylaxis 
during a cesarean section that was suspected to have been 
induced by the rocuronium–sugammadex complex. It is 
important to determine the pathogenesis of anaphylaxis by 
appropriate examinations to establish optimal risk reduc-
tion strategies and to prevent recurrence.
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